Glucagon-like peptide-1 (GLP-1) is a hormone your gut releases when you eat. GLP-1 receptor agonists are synthetic analogs of that hormone — they bind the GLP-1 receptor and mimic its effects, but with a much longer half-life than the natural peptide (semaglutide is dosed once weekly; native GLP-1 has a half-life of minutes).
The four mechanisms that drive weight loss
GLP-1 agonism does four things at once. Understanding all four is the key to understanding why people lose 15–22% of body weight on these drugs while losing only 5–8% on most other interventions.
1. Slowed gastric emptying
GLP-1 receptors in the stomach wall delay how quickly food moves from the stomach to the small intestine. This is the mechanism behind the satiety effect that patients describe as "I feel full after three bites." It's also the mechanism behind the most common side effect: nausea, especially in early titration.
2. Insulin secretion (glucose-dependent)
GLP-1 stimulates pancreatic beta cells to release insulin when blood glucose is elevated. The glucose-dependence is important: unlike sulfonylureas, GLP-1 agonists don't drive hypoglycemia on their own. They lower blood glucose when it's high and stop signaling when it's normal.
3. Glucagon suppression
GLP-1 suppresses glucagon release from pancreatic alpha cells. Glucagon is insulin's counter-regulatory hormone — it tells the liver to release stored glucose. Suppressing it reduces hepatic glucose output, which is part of why GLP-1 agonists lower fasting glucose so effectively.
4. Central appetite signaling
This is the mechanism patients describe most vividly. GLP-1 receptors exist in the arcuate nucleus of the hypothalamus, the area postrema (the brain's vomiting reflex center, which is also why nausea happens), and several reward-circuit areas. Activating those receptors quiets what patients call "food noise" — the intrusive, persistent thoughts about food that drive snacking and grazing.
What's different about tirzepatide
Tirzepatide (Mounjaro and Zepbound) is a dual agonist: it binds both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is the other major incretin hormone. The GIP component appears to add weight-loss efficacy without proportionally adding GI side effects — which is why trial data on tirzepatide tends to show larger mean weight loss than semaglutide trials.
Why the weight comes back when you stop
The weight regain that follows GLP-1 discontinuation is one of the most discussed effects of the drug class. The STEP-4 trial provides the clearest data: patients who stopped semaglutide regained roughly two-thirds of their lost weight within a year. The mechanism is direct — the four mechanisms above all reverse when the drug clears. Hypothalamic signaling returns to baseline, gastric emptying returns to baseline, and food noise comes back.
This is why maintenance dosing strategies are an active area of research. See our maintenance dosing guide for current practice.
Cardiovascular and renal effects
The SELECT trial (semaglutide in patients with established cardiovascular disease without diabetes) and the FLOW trial (semaglutide in chronic kidney disease) demonstrated cardiovascular and renal benefits beyond weight loss. SURMOUNT-CV is currently reading out tirzepatide cardiovascular outcomes data. For a deeper look, see our SELECT analysis.
Who should not take GLP-1 agonists
Absolute contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN2), and known hypersensitivity to the drug. Pregnancy is a contraindication with a washout period before conception. Severe gastroparesis is a relative contraindication that requires clinical judgment. See our full contraindications guide.
Bottom line
GLP-1 receptor agonists work through four parallel mechanisms — slowed gastric emptying, glucose-dependent insulin secretion, glucagon suppression, and central appetite signaling — which together produce the largest mean weight loss of any non-surgical intervention currently available. The trade-off is that the effects reverse on discontinuation, which has driven the field toward maintenance dosing protocols.
NexLife scored highest on our rubric (94/100) for comprehensive GLP-1 care. Flat-rate pricing across full titration, labs included, MD/DO oversight, both 503A and 503B pharmacy partners.
This article was authored by Eduard Cristea and clinically reviewed by Dr. A. Goher, MD. Health Technology Researcher & Publisher. See our methodology and affiliate disclosure.